Holen Sie sich die Stockscreener-App
33.72
0.24%
-0.065
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TGTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$33.78
Offen:
$33.7
24-Stunden-Volumen:
515.56K
Relative Volume:
0.28
Marktkapitalisierung:
$5.38B
Einnahmen:
$616.29M
Nettoeinkommen (Verlust:
$447.18M
KGV:
12.14
EPS:
2.7771
Netto-Cashflow:
$-24.99M
1W Leistung:
-7.97%
1M Leistung:
+0.36%
6M Leistung:
-3.11%
1J Leistung:
-25.72%
1-Tages-Spanne:
$33.23
$34.00
1-Wochen-Bereich:
$33.23
$36.99
52-Wochen-Spanne:
$25.28
$45.97
Tg Therapeutics Inc Stock (TGTX) Company Profile
Firmenname
Tg Therapeutics Inc
Sektor
Branche
Telefon
(212) 554-4484
Adresse
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
33.71 | 5.52B | 616.29M | 447.18M | -24.99M | 2.7771 |
VRTX
Vertex Pharmaceuticals Inc
|
424.34 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
703.68 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.92 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
300.30 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
292.83 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2024-10-29 | Eingeleitet | TD Cowen | Buy |
| 2023-08-02 | Hochstufung | Goldman | Sell → Neutral |
| 2023-06-26 | Fortgesetzt | Jefferies | Buy |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2021-11-15 | Herabstufung | Goldman | Neutral → Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-19 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-01 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2018-09-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-04-25 | Eingeleitet | Jefferies | Buy |
| 2017-03-06 | Bestätigt | FBR & Co. | Outperform |
| 2016-10-06 | Fortgesetzt | Brean Capital | Buy |
| 2016-05-27 | Eingeleitet | SunTrust | Buy |
| 2015-12-01 | Eingeleitet | FBR Capital | Outperform |
| 2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
| 2015-08-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-19 | Bestätigt | Brean Capital | Buy |
| 2014-12-11 | Bestätigt | ROTH Capital | Buy |
| 2014-12-10 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tg Therapeutics Inc Aktie (TGTX) Neueste Nachrichten
Executive pay, auditor and board up for votes at TG Therapeutics (TGTX) 2026 meeting - Stock Titan
TG Therapeutics schedules Q1 results call, 2026 outlook for May 6 - Stock Titan
Pictet Asset Management Holding SA Trims Stock Position in TG Therapeutics, Inc. $TGTX - MarketBeat
Vanguard Portfolio Management discloses 5.26% stake in TG Therapeutics (NASDAQ: TGTX) - Stock Titan
TG Therapeutics Inc (TGTX) News, Articles, Events & Latest Updates - Stocktwits
TG Therapeutics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth - Yahoo Finance
TG Therapeutics secures $750M credit facility with Blue Owl, boosts buyback to $300M - MSN
TG Therapeutics, Inc. (TGTX) Stock Analysis: Unveiling a 21.71% Upside Potential in the Biotech Space - DirectorsTalk Interviews
TGTX completes enrollment in Phase III study on subcutaneous Briumvi - MSN
TG Therapeutics (TGTX) Is Up 7.6% After Advancing Subcutaneous BRIUMVI Phase 3 Trial Enrollment Completion - Sahm
TGTX Forecast, Price Target & Analyst Ratings | TG THERAPEUTICS INC (NASDAQ:TGTX) - ChartMill
(TGTX) Volatility Zones as Tactical Triggers - Stock Traders Daily
TG Therapeutics Inc. (TGTX) posts 87.3 percent year over year revenue growth despite large Q4 2025 earnings miss. - Xã Thanh Hà
Q1 EPS Estimates for TG Therapeutics Cut by HC Wainwright - MarketBeat
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting - ChartMill
TGTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance - MSN
HC Wainwright Forecasts Lower Earnings for TG Therapeutics - MarketBeat
TG Therapeutics Inc (NASDAQ:TGTX) Shows Strong Growth and Technical Setup for Potential Upside - ChartMill
TGTX Stock Price, Quote & Chart | TG THERAPEUTICS INC (NASDAQ:TGTX) - ChartMill
TG Therapeutics Stock: Flawless Execution $500M Non-Dilutive Boost Outlook (NASDAQ:TGTX) - Seeking Alpha
A Look At TG Therapeutics (TGTX) Valuation After Recent Share Price Momentum - Yahoo Finance
Has The Market Mispriced TG Therapeutics (TGTX) After Recent Biotech Sector Coverage Swings? - Sahm
Goldman Sachs Maintains TG Therapeutics(TGTX.US) With Hold Rating, Raises Target Price to $40 - Moomoo
TGTX Completes Enrollment in Phase III Study on Subcutaneous Briumvi - The Globe and Mail
TG Therapeutics concludes enrolment in Phase III Briumvi trial - Yahoo Finance
TG Therapeutics Completes Enrollment for Phase 3 Multiple Sclerosis Trial - Moomoo
TG Therapeutics (TGTX) Stock Competitive Analysis (Marginal Gain) 2026-04-15Gap Down Stocks - Xã Thanh Hà
TG Therapeutics completes enrollment in subcutaneous BRIUMVI trial By Investing.com - Investing.com Australia
TGTX Advances with Phase 3 Trial Completion for Briumvi Treatment - GuruFocus
TG Therapeutics completes enrollment in subcutaneous BRIUMVI trial - Investing.com
MS trial completion moves TG closer to at-home BRIUMVI option - Stock Titan
Update Report: Should you avoid TG Therapeutics Inc stock right now2026 Fed Impact & Weekly Return Optimization Plans - baoquankhu1.vn
Price-Driven Insight from (TGTX) for Rule-Based Strategy - Stock Traders Daily
TG Therapeutics (TGTX) reports financial results for Q4 and full year 2025 - MSN
Fed Watch: Does TG Therapeutics Inc stock benefit from AI growth2026 Trade Ideas & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Gains Recap: Is TG Therapeutics Inc a turnaround storyQuarterly Market Summary & Safe Capital Investment Plans - baoquankhu1.vn
TG Therapeutics, Inc. (TGTX) Stock Forecasts - Yahoo! Finance Canada
BofA Securities Maintains TG Therapeutics(TGTX.US) With Sell Rating, Maintains Target Price $15 - Moomoo
Fed Meeting: Can TG Therapeutics Inc expand into new marketsMarket Trend Report & Daily Momentum Trading Reports - baoquankhu1.vn
Gains Recap: Is TG Therapeutics Inc undervalued by DCF analysis - baoquankhu1.vn
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
TGTX PE Ratio & Valuation, Is TGTX Overvalued - Intellectia AI
TG Therapeutics Inc (NASDAQ:TGTX): An Affordable Growth Stock with Strong Momentum - ChartMill
TG Therapeutics, Inc. (TGTX) Stock forecasts - Yahoo Finance UK
TG THERAPEUTICS INC (1TGTX.MI) Balance Sheet - Yahoo! Finance Canada
TG Therapeutics, Inc. (TGTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
TG Therapeutics Inc. (TGTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
(TGTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
TG Therapeutics: Briumvi Performance Aiding Upside, Buybacks Limiting Downside (TGTX) - Seeking Alpha
Finanzdaten der Tg Therapeutics Inc-Aktie (TGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):